SK609 HCl | CAS#1092797-77-7 | dopamine D3 receptor agonist

MedKoo Cat#: 562050 | Name: SK609 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SK609 HCl is a selective dopamine D3 receptor agonist with atypical signaling properties.

Chemical Structure

SK609 HCl

CAS#1092797-77-7

Theoretical Analysis

MedKoo Cat#: 562050

Name: SK609 HCl

CAS#: 1092797-77-7

Chemical Formula: C10H15Cl2N

Exact Mass: 0.0000

Molecular Weight: 220.13

Elemental Analysis: C, 54.56; H, 6.87; Cl, 32.21; N, 6.36

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 400.00	2 weeks
25mg	USD 850.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

144887-95-6

Synonym

SK609 hydrochloride; SK-609 hydrochloride; SK 609 hydrochloride; SK609 HCl; SK-609 HCl; SK 609 HCl; ES609; ES-609; ES 609;

IUPAC/Chemical Name

4-(2-Chlorophenyl)butan-2-amine hydrochloride

InChi Key

NVCYSMVSGDVJQR-UHFFFAOYSA-N

InChi Code

InChI=1S/C10H14ClN.ClH/c1-8(12)6-7-9-4-2-3-5-10(9)11;/h2-5,8H,6-7,12H2,1H3;1H

SMILES Code

CC(N)CCC1=CC=CC=C1Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO and water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SK609 is a dopamine D3 receptor (D3R) selective agonist with a bias towards the G-protein-dependent pathway and an EC50 value of 113.9 nM for activation of ERK1/2 phosphorylation. It does not induce desensitization of D3R.

In vitro activity:

To be determined

In vivo activity:

SK609 has the potential to treat sustained attention deficits without affecting dopamine transporter activity, unlike amphetamines and methylphenidate. In naïve rats, systemic SK609 dosing led to a 300% rise in norepinephrine and a 160% increase in dopamine. Notably, cognitive improvement was more pronounced in low-performing animals, and doses associated with this enhancement did not elevate spontaneous locomotor activity, indicating potential absence of side effects related to dopamine transporter activity. Reference: Neuropharmacology. 2019 Apr;148:178-188. https://pubmed.ncbi.nlm.nih.gov/30633928/

	Solvent	mg/mL	mM
Solubility
	Water	22.0	100.00
	DMSO	22.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 220.13 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Marshall CA, Brodnik ZD, Mortensen OV, Reith MEA, Shumsky JS, Waterhouse BD, España RA, Kortagere S. Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention. Neuropharmacology. 2019 Apr;148:178-188. doi: 10.1016/j.neuropharm.2019.01.003. Epub 2019 Jan 8. PMID: 30633928; PMCID: PMC6424628. 2. Simms SL, Huettner DP, Kortagere S. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease. Neuropharmacology. 2016 Jan;100:106-15. doi: 10.1016/j.neuropharm.2015.04.004. Epub 2015 Apr 18. PMID: 25896768.

In vitro protocol:

To be determined

In vivo protocol:

1: Xu W, Wang X, Tocker AM, Huang P, Reith ME, Liu-Chen LY, Smith AB 3rd, Kortagere S. Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists. ACS Chem Neurosci. 2017 Mar 15;8(3):486-500. doi: 10.1021/acschemneuro.6b00221. Epub 2016 Nov 23. PubMed PMID: 27801563. 2: Simms SL, Huettner DP, Kortagere S. In vivo characterization of a novel dopamine D3 receptor agonist to treat motor symptoms of Parkinson's disease. Neuropharmacology. 2016 Jan;100:106-15. doi: 10.1016/j.neuropharm.2015.04.004. Epub 2015 Apr 18. PubMed PMID: 25896768.